Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study
BU is an impactful symptom among Japanese patients with UC and CD and should be considered by HCPs during treatment of these conditions.
Authors
- Theresa Hunter (ORCID: https://orcid.org/0000-0001-8412-9175)
- Satoshi Osaga (ORCID: https://orcid.org/0000-0003-4459-2469)
- Toshifumi Hibi∥ (ORCID: https://orcid.org/0000-0002-6256-1204)
- Marijana Protić (ORCID: https://orcid.org/0009-0009-2172-8598)
- Tadakazu Hisamatsu (ORCID: https://orcid.org/0000-0002-1178-3536)
- Taku Kobayashi (ORCID: https://orcid.org/0000-0002-2073-4234)
- Alison Potts Bleakman (ORCID: https://orcid.org/0000-0001-8373-6299)
- Isabel Redondo
- Masaru Tanaka (ORCID: https://orcid.org/0009-0008-7302-8692)
- Koji Matsuo (ORCID: https://orcid.org/0000-0002-4862-8927)
Institutions
- Eli Lilly (United States) (US)
- Kyorin University (JP)
- Eli Lilly (Japan) (JP)
- Kitasato Institute Hospital (JP)
- Kitasato University (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1007/s12325-024-03078-3
- Citations
- 4
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 7.27
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- EA Pharma Co., Ltd.
- Celltrion
- Mitsubishi Tanabe Pharma Corporation
- Eli Lilly Japan